ProShares UltraShort NASDAQ Biotechnology
8 hedge funds and large institutions have $7.11M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
0.53% more ownership
Funds ownership: 5.01% → 5.55% (+0.53%)
27% less funds holding
Funds holding: 11 → 8 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
8
Holding in Top 10
2
Calls
$559K
Puts
$467K
Top Buyers
| 1 | +$557K | |
| 2 | +$470K | |
| 3 | +$63K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.7K |
Top Sellers
| 1 | -$1.05M | |
| 2 | -$545K | |
| 3 | -$520K | |
| 4 |
Citigroup
New York
|
-$25.9K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$22K |